Core Viewpoint - The company,拓新药业, is forecasting a significant increase in losses for the fiscal year 2025, projecting a loss between 54 million to 73 million yuan, which is a substantial increase compared to the previous year's loss of approximately 19.88 million yuan [1]. Financial Performance - For the first three quarters of 2025, the company's operating revenue decreased by 16.64%, with a net loss of approximately 30.16 million yuan, indicating that the fourth quarter of the previous year alone saw losses exceeding the total losses of the first three quarters [1]. - The company has reported consecutive annual losses for two years, with the loss margin increasing significantly [1]. Management Response - In response to the ongoing losses, the company is actively implementing multiple measures aimed at improving operational performance and achieving profitability [1][2]. - The company acknowledges that the decline in overall business performance is primarily due to fluctuations in demand and declining market prices for certain raw material products, which have adversely affected sales revenue and gross margins [2]. - The company is also facing high fixed costs due to the gradual release of new production capacity from completed investment projects, which is putting pressure on current profits [2]. Shareholder Actions - The company's major shareholder, 伊沃斯, has reduced its stake in the company, decreasing its ownership from 29.84% to 27.37% after a series of share reductions totaling 3.12 million shares [3]. - Despite an influx of financing in 2026, the company's financing balance has decreased, falling to 136 million yuan from 144 million yuan, a decline of over 6% [3].
拓新药业亏损金额进一步扩大！互动易上投资者追问扭转连亏困局方案